Idogen’s financial contribution from Horizon 2020 now finalizes with a publication
Idogen AB (publ) today announces that an article about our IDO 8 program, is now published on the European Commission’s CORDIS website. The article summarizes the results of the financial contribution of about 2.86 MEUR (about 29 MSEK) granted to Idogen by Horizon 2020, EU’s framework of research and innovation, in May 2017. The purpose of the grant was to develop the company’s tolerogenic cell therapy for treating severe hemophilia patients who have developed neutralizing antibodies against their treatment with factor VIII. ”The grant from EU’s Horizon 2020 have really